Verquvo Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Adverse Reactions

Clinical Trials Experience: Vericiguat (Verquvo) was evaluated in VICTORIA, a Phase 3 randomized, placebo controlled, double-blind, clinical trial in adult patients with symptomatic chronic heart failure and ejection fraction less than 45% following a worsening heart failure event, which included a total of 2,519 patients treated with Vericiguat (Verquvo) (up to 10 mg once daily) and 2,515 patients treated with matching placebo [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions]. The mean duration of Vericiguat (Verquvo) exposure was 1 year, and the maximum duration was 2.6 years. Table 7 lists adverse drug reactions occurring in patients treated with Vericiguat (Verquvo) and greater than placebo in VICTORIA. (See Table 7.)

Click on icon to see table/diagram/image

View ADR Reporting Link

vericiguat

Manufacturer:

Bayer AG

Distributor:

Bayer